Oral CEP-701
C0701/2025/ON/US
Phase 2 small_molecule terminated
Quick answer
Oral CEP-701 for Myeloma is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated